Flax Pond Capital LLC Takes $1.23 Million Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Flax Pond Capital LLC bought a new stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 173,633 shares of the company’s stock, valued at approximately $1,229,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BCYC. Assetmark Inc. boosted its holdings in Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares in the last quarter. Clearstead Advisors LLC grew its stake in Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares during the period. Brooklyn Investment Group bought a new stake in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $69,000. Ausdal Financial Partners Inc. bought a new stake in shares of Bicycle Therapeutics during the second quarter valued at approximately $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new position in shares of Bicycle Therapeutics during the fourth quarter worth approximately $71,000. 86.15% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BCYC has been the topic of a number of recent research reports. Royal Bank Of Canada cut their target price on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 18th. Morgan Stanley reduced their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Oppenheimer decreased their target price on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating for the company in a research report on Wednesday, March 18th. Needham & Company LLC lowered their target price on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a report on Tuesday, March 17th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.00.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $4.00 on Friday. The company has a market capitalization of $278.89 million, a P/E ratio of -1.27 and a beta of 1.54. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.95 and a fifty-two week high of $9.18. The stock has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $5.52.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The company had revenue of $0.89 million during the quarter, compared to the consensus estimate of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. As a group, equities analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 earnings per share for the current year.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,967 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total value of $29,297.97. Following the transaction, the chief executive officer owned 613,029 shares of the company’s stock, valued at $3,009,972.39. This trade represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,992 shares of company stock worth $49,363 in the last 90 days. Corporate insiders own 22.90% of the company’s stock.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.